ALK and non-small cell lung carcinoma: In a randomized phase 3 trial involving patients with advanced ALK-positive NSCLC who had received previous platinum-based chemotherapy, crizotinib was superior to single-agent second-line chemotherapy with either pemetrexed or docetaxel [10].